Comparison · NCT04334148-ba1469c8
Hydroxychloroquine vs Placebo: Number of Participants With Clinical Infection With COVID-19 Infection
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Hydroxychloroquine vs Placebo: Number of Participants With Clinical Infection With COVID-19 Infection. Trial comparisons, record NCT04334148-ba1469c8. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04334148-ba1469c8
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.06 | 0.0446 | 0.0804 | wilson | |
| Risk in group 2 | 0.0784 | 0.0604 | 0.101 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0184 | -0.0459 | 0.00881 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.766 | 0.517 | 1.13 | log | |
| Odds ratio, group 1 over group 2 | 0.751 | 0.492 | 1.15 | log | |
| Number needed to treat, for one fewer participant with the outcome on Hydroxychloroquine than on Placebo | 54.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Hydroxychloroquine | Hydroxychloroquine tablet 600mg bid loading dose on day 1 followed by 400mg on days 2-30.~Hydroxychloroquine: oral self administered tablet | 41 | 683 | OG000 |
| Group 2 | Placebo | Matching placebo tablets~Placebo oral tablet: oral self administered tablet | 53 | 676 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Clinical Infection With COVID-19 Infection
- Description
This measure was a combination of confirmed infection and suspected infection. Confirmed clinical infection was defined as new-onset of fever or cough or dyspnea AND confirmed COVID-19 positive test result via local PCRI testing. Suspected infection was defined as new-onset fever or cough or dyspnea without local PCR testing due to local restrictions and/or testing policies.
- Time frame
- 30 days
- Population
- Participants who completed the study.
Source ClinicalTrials.gov
Trial
- Title
- Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine
- NCT number
- NCT04334148
- Phases
- PHASE3
- Conditions
- COVID-19
- Interventions
- Hydroxychloroquine, Placebo oral tablet
- Lead sponsor
- Adrian Hernandez
- Results first posted
- 2021-10-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04334148?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04334148-ba1469c8